NanoPhoria
N
Active
Developing inhalable therapies for cardiovascular diseases using a proprietary nanoparticle platform.
NanoPhoria
Developing inhalable therapies for cardiovascular diseases using a proprietary nanoparticle platform.
About
NanoPhoria is a preclinical-stage biotechnology company focused on developing novel inhalable therapies for cardiovascular diseases. Their core technology utilizes a proprietary, non-viral calcium phosphate nanoparticle platform designed to deliver biologics, such as peptides and RNA, directly to target tissues. This approach aims to enhance treatment effectiveness and minimize systemic side effects by enabling precise, tissue-directed drug delivery via inhalation, with an initial focus on conditions like heart failure.
Tags
Performance
Company Timeline
No timeline data for this period
Score Breakdown
25Traction
40Team
0Visibility
2Profile
35Community
10Discussion (0)
Join the discussion
No comments yet. Be the first to share your thoughts!
Frequently Asked Questions
What does NanoPhoria do?
NanoPhoria is a preclinical-stage biotechnology company focused on developing novel inhalable therapies for cardiovascular diseases. Their core technology utilizes a proprietary, non-viral calcium phosphate nanoparticle platform designed to deliver biologics, such as peptides and RNA, directly to target tissues. This approach aims to enhance treatment effectiveness and minimize systemic side effects by enabling precise, tissue-directed drug delivery via inhalation, with an initial focus on condi…
How much funding has NanoPhoria raised?
NanoPhoria has raised a total of $84M in funding. The most recent round on record is null.
Where is NanoPhoria headquartered?
NanoPhoria is headquartered in Italy.
What industry does NanoPhoria operate in?
NanoPhoria operates in Biotechnology, Healthcare, Pharmaceuticals, Medical Devices.